Q2 2021 Results - Reimagining Medicine
Participants
Financial review
Conclusion
Appendix
Company overview
Pharmaceuticals
Oncology
Financial performance
Innovation: Pipeline overview
Novartis pipeline in registration
Oncology
Code
Name
Mechanism
Indication(s)
References
Innovation: Clinical trials
Cardiovascular, Renal, Metabolism
Chronic GVHD
Code Name
KJX839 Leqvio®
Mechanism
siRNA (regulation of LDL-C)
Indication(s)
Hyperlipidemia1
INC424 Jakavi®
ABL001
asciminib
JAK1/2 inhibitor
BCR-ABL inhibitor
Acute GVHD
Chronic myeloid leukemia, 3rd line
Immunology, Hepatology, Dermatology
Code
AIN457
Name
Cosentyx®
1. Approved in EU.
Mechanism
IL17A inhibitor
52 Investor Relations | Q2 2021 Results
Indication(s)
Cosentyx 300mg auto-injector and pre-filled syringe
Juvenile idiopathic arthritis
2 lead indication
Lead indication
NOVARTIS | Reimagining MedicineView entire presentation